

Donald W. Landry and Juan A. Oliver

U.S. Serial No. 10/789,548

Filed: February 26, 2004

Page 2

In the claims:

Applicants present all pending claims with status indicator in compliance with the practice guidelines for making amendments under 37 C.F.R. §1.121(c) (1).

1. (currently amended) A method for reducing excess extracellular fluid in a subject undergoing hemodialysis comprising administering a vasopressin (V-1) receptor agonist to the subject in an effective amount and thereby maintaining blood pressure during hemodialysis in order to facilitate reducing excess extracellular fluid in the subject.
2. (original) A method for stabilizing high blood pressure between hemodialysis treatments in a subject undergoing hemodialysis by reducing excess extracellular fluid by the method of claim 1.
3. (original) A method for inhibiting interdialytic hypertension by regulating blood pressure by the method of claim 2.
4. (original) A method for inhibiting intradialytic hypotension by regulating blood pressure by the method of claim 1.
5. (original) The method of claim 1, wherein the V-1 receptor agonist is arginine vasopressin.
6. (original) The method of claim 1, wherein the V-1 receptor agonist is lysine vasopressin.
7. (original) The method of claim 1, wherein the V-1 receptor agonist is terlipressin.

Donald W. Landry and Juan A. Oliver

U.S. Serial No. 10/789,548

Filed: February 26, 2004

Page 3

8. (original) The method of claim 1, wherein the V-1 receptor agonist is octapressin
9. (original) The method of claim 1, wherein the V-1 receptor agonist is ornipressin
10. (original) The method of claim 1, wherein the V-1 receptor agonist is an organic molecule selected from the group consisting of 3-beta-(2-thienyl)-L-alanine)-8-lysine-vasopressin, N-alpha-glycyl-glycyl-glycyl-[8-lysine]-vasopressin, and 1-deamino-6-carba-[8-arginine]-vasopressin.
11. (original) The method of claim 1, wherein the effective amount of the V-1 receptor agonist is in a range of about 0.05 milliunits/kg/minute - 2.0 milliunits/kg/hr.
12. (original) The method of claim 1, wherein the effective amount of the V-1 receptor agonist is about 0.3 milliunits/kg/minute.
13. (original) The method of claim 1, wherein the subject is a human, non-human primate, rabbit, sheep, rat, dog, cat, pig, or mouse.